Research ArticleEndocrine and Diabetes
Beneficial effects of PKF275-055, a novel, selective, and orally bioavailable, long-acting dipeptidyl peptidase IV inhibitor in streptozotocin-induced diabetic peripheral neuropathy
Roberto Bianchi, Ilaria Cervellini, Carla Porretta-Serapiglia, Norberto Oggioni, Byan Burkey, Pietro Ghezzi, Guido Cavaletti and Giuseppe Lauria
Journal of Pharmacology and Experimental Therapeutics October 7, 2011, jpet.111.181529; DOI: https://doi.org/10.1124/jpet.111.181529
Roberto Bianchi
Ilaria Cervellini
Carla Porretta-Serapiglia
Norberto Oggioni
Byan Burkey
Pietro Ghezzi
Guido Cavaletti
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleEndocrine and Diabetes
Beneficial effects of PKF275-055, a novel, selective, and orally bioavailable, long-acting dipeptidyl peptidase IV inhibitor in streptozotocin-induced diabetic peripheral neuropathy
Roberto Bianchi, Ilaria Cervellini, Carla Porretta-Serapiglia, Norberto Oggioni, Byan Burkey, Pietro Ghezzi, Guido Cavaletti and Giuseppe Lauria
Journal of Pharmacology and Experimental Therapeutics October 7, 2011, jpet.111.181529; DOI: https://doi.org/10.1124/jpet.111.181529
Research ArticleEndocrine and Diabetes
Beneficial effects of PKF275-055, a novel, selective, and orally bioavailable, long-acting dipeptidyl peptidase IV inhibitor in streptozotocin-induced diabetic peripheral neuropathy
Roberto Bianchi, Ilaria Cervellini, Carla Porretta-Serapiglia, Norberto Oggioni, Byan Burkey, Pietro Ghezzi, Guido Cavaletti and Giuseppe Lauria
Journal of Pharmacology and Experimental Therapeutics October 7, 2011, jpet.111.181529; DOI: https://doi.org/10.1124/jpet.111.181529
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement